Aura Biosciences Launches Stock Offering with Pre-Funded Warrants, 15% Overallotment Option
Aura Biosciences announced an underwritten public offering of its common stock and pre-funded warrants, with a 30-day option for underwriters to purchase up to 15% additional shares on the same terms. The offering is fully by Aura and remains subject to market conditions and final terms.
1. Offering Launch and Scope
Aura Biosciences launched an underwritten public offering of its common stock and, in lieu of stock to selected investors, pre-funded warrants to purchase shares. The company has granted underwriters a 30-day option to buy up to 15% more shares and warrants on identical terms.
2. Market Conditions and Timeline
The offering is filed under a shelf registration declared effective April 5, 2024, and will be completed only if market conditions are favorable. Final pricing, share count and other terms will be disclosed in a subsequent prospectus supplement.
3. Implications for Existing Shareholders
All securities are sold directly by Aura Biosciences, potentially diluting current shareholders depending on the final size of the deal. Net proceeds are expected to fund late-stage development of its lead candidate bel-sar (AU-011) and other clinical programs.